埃普莱伦治疗中枢血清性视网膜病变患者的影响:一项双盲随机临床试验
Mohammadreza Akhlaghi1, Alireza Dehghani1, Farzan Kianersi1
1Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran.
Journal of current ophthalmology
|November 18, 2024
概括
在治疗急性中央血清性胆色素变异症 (CSCR) 时,eplerenone 显示出有利的短期效应. 这项研究突出显示了矿物质皮质类受体在视网膜状况中的作用.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 中央血清性胆色素变异症 (CSCR) 是一种影响视力的疾病.
- 了解CSCR的潜在机制和有效治疗方法至关重要.
研究的目的:
- 评估eplerenone在患有中央血清性胆色素变异症 (CSCR) 的患者中的疗效.
- 评估eplerenone对CSCR患者视力敏度和视网膜厚度的影响.
主要方法:
- 进行了一项双盲临床试验,使用了天真的急性CSCR患者.
- 患者被随机分为两个组:eplerenone治疗 (25mg/50mg每天) 和安慰剂.
- 光学连贯断层扫描 (OCT) 用于在1个月前和1个月后测量最佳校正的视敏度 (BCVA),中央黄斑厚度 (CMT),黄斑体积 (MV) 和冠状腺厚度 (CT).
主要成果:
- 与安慰剂组 (P=0.052) 相比,在eplerenone治疗组 (P=0.002) 中,BCVA显著改善.
- 虽然CT,CMT和MV在每个组内显著改善,但在eplerenone和安慰剂组之间没有发现显著差异.
- 该研究包括治疗组的31名患者和安慰剂组的25名患者,平均年龄约为36岁.
结论:
- 在急性CSCR患者中,eplerenone表现出有利的短期临床效应.
- 这些发现表明,矿物质皮质类受体在CSCR的病理生理学中起着重要作用.
- 进一步的研究可能会探索eplerenone在CSCR治疗中的长期疗效和精确机制.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
495
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
495
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
135
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
481
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
481
01:27Open Angle Glaucoma: Treatment
393
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
393